Immunomodulators
US9809625B2 · kind B2 · utility
8Cited by
4References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 14, 2016 |
| Grant date | Nov 7, 2017 |
| Priority date | — |
| Expiry date | Mar 14, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K7/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.